<DOC>
	<DOCNO>NCT00143026</DOCNO>
	<brief_summary>This study examine effect treatment levodopa/entacapone quality life , measure Parkinson 's Disease-Questionnaire 8 ( PDQ-8 ) , Parkinson 's disease patient minimal , non-disabling motor fluctuation .</brief_summary>
	<brief_title>Study Compare Effect Treatment With Carbidopa/Levodopa/Entacapone Quality Life Patients With Parkinson 's Disease . This Study Not Recruiting United States</brief_title>
	<detailed_description>This study examine effect treatment levodopa/entacapone quality life , measure Parkinson 's Disease-Questionnaire 8 ( PDQ-8 ) , Parkinson 's disease patient minimal , non-disabling motor fluctuation . Treatment carbidopa/levodopa/entacapone compare treatment standard formulation levodopa/carbidopa .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Clinical diagnosis idiopathic Parkinson 's disease exhibit least 2 3 symptom Motor function must regard nondisabling patient History , sign symptom suggest diagnosis atypical secondary parkinsonism History dyskinesia Previous current use entacapone tolcapone Unstable Parkinson 's disease patient requiring/receiving regimen levodopa Subjects take levodopa/DDCI control release extend release formulation</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson 's disease , levodopa , motor fluctuation</keyword>
</DOC>